Results 21 to 30 of about 1,744 (184)
Comparative efficacy and safety of antibiotics used to treat acute bacterial skin and skin structure infections: Results of a network meta-analysis. [PDF]
PLoS ONE, 2017 ObjectiveThis NMA compared the efficacy and safety between IV antibiotics that are used in the current standard of care for managing adult patients (≥18 years of age) with ABSSSI.MethodsComparators were chosen on the basis that both direct and indirect ...
Julian F Guest +5 more
doaj +3 more sources
FDA Guidance for ABSSSI Trials: Implications for Conducting and Interpreting Clinical Trials [PDF]
Clinical Infectious Diseases, 2013 Recent guidance from the US Food and Drug Administration (FDA) on the conduct of clinical trials for acute bacterial skin and skin structure infection (ABSSSI) has changed the framework for clinical trial design and conduct. Notable changes included new disease state definitions, new primary endpoint definitions and the timing of assessments at these ...
Kamal M F, Itani, Andrew F, Shorr
openaire +2 more sources
Scandinavian Journal of Immunology, Volume 98, Issue 3, September 2023., 2023 Abstract Immune checkpoint inhibitors (ICIs) represent the cornerstone of the current treatment of non‐small cell lung cancer (NSCLC). However, the occurrence of concomitant infections might hamper success. All consecutive patients with advanced NSCLC who started ICIs as a first‐ or second‐line therapy from January 1, 2017 to June 30, 2020 were ...
Davide Fiore Bavaro +12 more
wiley +1 more source
Novel antimicrobial strategies to treat multi‐drug resistant Staphylococcus aureus infections
Microbial Biotechnology, Volume 16, Issue 7, Page 1456-1474, July 2023., 2023 Summary of novel strategies currently being developed to treat multi‐drug resistant Staphylococcus aureus infections. Abstract Antimicrobial resistance is a major obstacle for the treatment of infectious diseases and currently represents one of the most significant threats to global health. Staphylococcus aureus remains a formidable human pathogen with
Edward J. A. Douglas +3 more
wiley +1 more source
Global trends of dalbavancin: A bibliometric analysis
Journal of Clinical Pharmacy and Therapeutics, Volume 47, Issue 9, Page 1299-1311, September 2022., 2022 The bibliometric study identifies the most significant research on dalbavancin. We searched the Web of Science and found 675 documents. After ranking them by the number of times cited, we extracted T100. VOSviewer help us to identify keywords. Our study identifies the most significant research on dalbavancin, including the highest impact publications ...
Nuria Monteagudo‐Martínez +4 more
wiley +1 more source
International Wound Journal, Volume 19, Issue 5, Page 987-995, August 2022., 2022 Abstract The COVID‐19 pandemic deeply impacted the capacity of the health systems to maintain preventive and curative services, especially for the most vulnerable populations. During the pandemic, the wound healing centres in Italy assisted a significant reduction of the frequency of their hospital admission, since only urgencies, such as severe ...
Alessandro Scalise +7 more
wiley +1 more source
British Journal of Clinical Pharmacology, Volume 88, Issue 2, Page 416-428, February 2022., 2022 Aims To develop physiologically based pharmacokinetic (PBPK) and population pharmacokinetic (PopPK) models to predict effective doses of gepotidacin in paediatrics for the treatment of pneumonic plague (Yersinia pestis). Methods A gepotidacin PBPK model was constructed using a population‐based absorption, distribution, metabolism and excretion ...
Dung Nguyen +9 more
wiley +1 more source
Drugs in Context, 2023 Background: Recent recommendations by the American Society of Health System Pharmacists and Infectious Disease Society of America have provided guidance regarding vancomycin dosing and monitoring in serious infections (including methicillin-resistant ...
Andrew Merker +3 more
doaj +1 more source
Efficacy and safety of ceftobiprole in patients aged 65 years or older:a post hoc analysis of three Phase III studies [PDF]
, 2021 Lay abstract Infections are a common cause of severe disease and death in older patients. Antibiotic treatment may also be complicated by age-related changes within the body.
Engelhardt, Marc +5 more
core +1 more source
Critical Care Research and Practice, Volume 2022, Issue 1, 2022., 2022 Levonadifloxacin (intravenous) and its oral prodrug alalevonadifloxacin are broad‐spectrum antibacterial agents developed for the treatment of difficult‐to‐treat infections caused by multidrug‐resistant Gram‐positive bacteria, especially methicillin‐resistant Staphylococcus aureus, atypical bacteria, anaerobic bacteria, and biodefence pathogens as well
Yatin Mehta +6 more
wiley +1 more source